



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Hu Ma

✉ mahuab@163.com

Sisi He

✉ sisihe1219@163.com

†These authors have contributed
equally to this work and share
first authorship

RECEIVED 23 October 2024

ACCEPTED 25 November 2024

PUBLISHED 02 December 2024

CITATION

Meng M, Yu B, Luo J, Bai Y, Li L, Chen S,
He S and Ma H (2024) Corrigendum:
Case report: A sustained survival benefit of
third-line immunotherapy for refractory
thymic carcinoma.
Front. Oncol. 14:1516024.
doi: 10.3389/fonc.2024.1516024

COPYRIGHT

© 2024 Meng, Yu, Luo, Bai, Li, Chen, He and
Ma. This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums
is permitted, provided the original author(s)
and the copyright owner(s) are credited and
that the original publication in this journal is
cited, in accordance with accepted academic
practice. No use, distribution or reproduction
is permitted which does not comply with
these terms.

Corrigendum: Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

Mi Meng^{1†}, Bo Yu^{2†}, Jie Luo³, Yuju Bai¹, Lin Li¹, Shicheng Chen²,
Sisi He^{1*} and Hu Ma^{1*}

¹Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China, ²Department of Urology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China, ³Department of Radiation Oncology, Guiqian International General Hospital, Guiyang, China

KEYWORDS

sintilimab, thymic carcinoma(TC), therapeutic option, case report, anti-PD-1

A Corrigendum on

Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

By Meng M, Yu B, Luo J, Bai Y, Li L, Chen S, He S and Ma H (2024). *Front. Oncol.* 14:1326006.
doi: 10.3389/fonc.2024.1326006

In the published article, there was an error in affiliation 1. Instead of “Department of Thoracic Oncology, Affiliated Hospital of Zunyi Medical College, Zunyi, China”, it should be “Department of Thoracic Oncology, The second Affiliated Hospital of Zunyi Medical University, Zunyi, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.